Leukemia Research
Volume 34, Issue 10 , Pages 1320-1324 , October 2010

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

  • Jean-Marie Bruey

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • ,
  • Hagop Kantarjian

      Affiliations

    • Department of Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Wanlong Ma

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • ,
  • Zeev Estrov

      Affiliations

    • Department of Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Chenhsiung Yeh

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • ,
  • Amber Donahue

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • ,
  • Heather Sanders

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • ,
  • Susan O’Brien

      Affiliations

    • Department of Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Michael Keating

      Affiliations

    • Department of Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    • ,
  • Maher Albitar

      Affiliations

    • Department of Hematology and Oncology R&D, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 949 728 4784; fax: +1 949 728 7781.

Received 17 November 2009 ,Revised 19 January 2010 ,Accepted 4 March 2010.

References 

  1. Rozman C, Montserrat E. Chronic lymphocytic leukemia 11. N Engl J Med. 1995;333:1052–1057
  2. Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy 7. Ann Oncol. 1997;8(Suppl. 1):93–101
  3. Sanhes L, Tang R, Delmer A, DeCaprio JA, Jchenbaum-Cymbalista F. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases 1. Leukemia. 2003;17:1104–1111
  4. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, et al The triterpenoid CDDO induces apoptosis in refractory CLL B cells 17. Blood. 2002;100:2965–2972
  5. Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993;11:1985
  6. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–237
  7. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322
  8. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17:489–503
  9. Sulik M, Guzinska-Ustymowicz K. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer. Rocz Akad Med Bialymst. 2002;47:262–269
  10. Ferrara C, Tessari G, Poletti A, Giacon C, Meggiato T, Martines D, et al. Ki-67 and c-jun expression in pancreatic cancer: a prognostic marker?. Oncol Rep. 1999;6:1117–1122
  11. Oshima CT, Iriya K, Forones NM. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52:420–424
  12. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–7220
  13. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815
  14. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, et al. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia 1. Leuk Res. 2009;
  15. Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol. 2008;61:569–577
  16. Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;
  17. Hrushesky WJ, Retsky M, Baum M, Demicheli R. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:1053–1054
  18. Gallee MP, van Steenbrugge GJ, ten Kate FJ, Schroeder FH, van der Kwast TH. Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst. 1987;79:1333–1340
  19. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. Histopathology. 2007;51:491–498
  20. Nomura Y, Yoshida S, Karube K, Takeshita M, Hirose S, Nakamura S, et al. Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci. 2008;99:1564–1569
  21. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia 18. N Engl J Med. 2005;352:804–815
  22. de MN, Matutes E, Cordone I, Morilla R, Catovksy D. Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders 20. J Clin Pathol. 1992;45:660–663
  23. Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M, Guinan P. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol. 1998;67:33–37
  24. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998;82:168–175
  25. Khatami A, Hugosson J, Wang W, Damber JE. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol. 2009;43:12–18
  26. Hrushesky WJ, Retsky M, Baum M, Demicheli R, Re: . Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:1053–1054
  27. Diop S, Letestu R, Orsolani D, Leboeuf Y, Le Tutour P, Thiam D, et al. [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia] 19. Dakar Med. 2005;50:65–68
  28. Aaltomaa S, Kärjä V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res. 2006;26:4873–4878
  29. Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  30. Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, et al Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2004;103:2799–2801
  31. Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo 1. Int J Cancer. 2003;105:710–716
  32. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003;123:850–857
  33. Giles FJ, Albitar M. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Expert Rev Mol Diagn. 2007;7:615–623
  34. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O’Brien S, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999–1008
  35. Remes K, Tienhaara A, Pelliniemi TT. Effects of alpha-interferon on serum beta-2-microglobulin 2. Leuk Lymphoma. 1996;21:233–238
  36. Zheng JN, Pei DS, Mao LJ, Liu XY, Mei DD, Zhang BF, et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 2009;16:20–32
  37. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 1997;115:229–234

PII: S0145-2126(10)00151-7

doi: 10.1016/j.leukres.2010.03.010

Leukemia Research
Volume 34, Issue 10 , Pages 1320-1324 , October 2010

Article Tools

* Image Usage & Resolution